A Novel Metal-Based Imaging Probe for Targeted Dual-Modality SPECT/MR Imaging of Angiogenesis
Kastis, George A.
Harris, Adrian L.
Furenlid, Lars R.
Moulopoulos, Lia A.
AffiliationUniv Arizona, Coll Opt Sci
MetadataShow full item record
PublisherFRONTIERS MEDIA SA
CitationTsoukalas C, Psimadas D, Kastis GA, Koutoulidis V, Harris AL, Paravatou-Petsotas M, Karageorgou M, Furenlid LR, Moulopoulos LA, Stamopoulos D and Bouziotis P (2018) A Novel Metal-Based Imaging Probe for Targeted Dual-Modality SPECT/MR Imaging of Angiogenesis. Front. Chem. 6:224. doi: 10.3389/fchem.2018.00224
JournalFRONTIERS IN CHEMISTRY
Rights© 2018 Tsoukalas, Psimadas, Kastis, Koutoulidis, Harris, Paravatou-Petsotas, Karageorgou, Furenlid, Moulopoulos, Stamopoulos and Bouziotis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractSuperparamagnetic iron oxide nanoparticles with well-integrated multimodality imaging properties have generated increasing research interest in the past decade, especially when it comes to the targeted imaging of tumors. Bevacizumab (BCZM) on the other hand is a well-known and widely applied monoclonal antibody recognizing VEGF-A, which is overexpressed in angiogenesis. The aim of this proof-of-concept study was to develop a dual-modality nanoplatform for in vivo targeted single photon computed emission tomography (SPECT) and magnetic resonance imaging (MRI) of tumor vascularization. Iron oxide nanoparticles (IONPs) have been coated with dimercaptosuccinic acid (DMSA), for consequent functionalization with the monoclonal antibody BCZM radiolabeled with Tc-99m, via well-developed surface engineering. The IONPs were characterized based on their size distribution, hydrodynamic diameter and magnetic properties. In vitro cytotoxicity studies showed that our nanoconstruct does not cause toxic effects in normal and cancer cells. Fe3O4-DMSA-SMCC-BCZM-Tc-99m were successfully prepared at high radiochemical purity (> 92%) and their stability in human serum and in PBS were demonstrated. In vitro cell binding studies showed the ability of the Fe3O4-DMSA-SMCC-BCZM-Tc-99m to bind to the VEGF-165 isoform overexpressed on M-165 tumor cells. The ex vivo biodistribution studies in M165 tumor-bearing SCID mice showed high uptake in liver, spleen, kidney and lungs. The Fe3O4-DMSA-SMCC-BCZM-Tc-99m demonstrated quick tumor accumulation starting at 8.9 +/- 1.88% ID/g at 2 h p.i., slightly increasing at 4 h p.i. (16.21 +/- 2.56% ID/g) and then decreasing at 24 h p.i. (6.01 +/- 1.69% ID/g). The tumor-to-blood ratio reached a maximum at 24 h p.i. (similar to 7), which is also the case for the tumor-to- muscle ratio (similar to 18). Initial pilot imaging studies on an experimental gamma-camera and a clinical MR camera prove our hypothesis and demonstrate the potential of Fe3O4-DMSA-SMCC-BCZM-Tc-99m for targeted dual-modality imaging. Our findings indicate that Fe3O4-DMSA-SMCC-BCZM-Tc-99m IONPs could serve as an important diagnostic tool for biomedical imaging as well as a promising candidate for future theranostic applications in cancer.
NoteOpen access journal.
VersionFinal published version